尖峰集团(600668.SH)子公司获得富马酸伏诺拉生化学原料药上市申请批准通知书

Core Viewpoint - The announcement indicates that尖峰集团's subsidiary, 安徽尖峰北卡药业有限公司, has received approval from the National Medical Products Administration for the chemical raw material drug Vonoprazan Fumarate, which is a potassium ion competitive acid blocker used for treating gastroesophageal reflux disease [1] Group 1 - The approval notification number for the drug is 2025YS00694, confirming that the drug meets the national technical standards for chemical raw material drug review [1] - Vonoprazan Fumarate was developed by Takeda Pharmaceutical Company Limited in Japan [1] - The approval allows尖峰北卡 to sell the drug in the domestic market, which will help expand the subsidiary's business scope [1]